EUVIMEDEUVIMED entdecken
Crossref

Dual-Targeting Chitosan Nanogels Enable Magnetic Resonance Imaging-Guided Synergistic Chemo/Chemodynamic Therapy against Prostate Cancer Bone Metastasis

Jiahui Liu, Jinxia Wang, Aiyu Li, Yifan Huang, Lili Xia, Jia Yang, Jianjun Zhang, Xiangyang Shi, Mingwu Shen

Biomacromolecules · 11.11.2026

DOI: 10.1021/acs.biomac.6c01943 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomacromolecules, online erschienen am 11.11.2026. Verfasst von Jiahui Liu und 8 weiteren Autor:innen. Die Arbeit nennt 53 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality, National Natural Science Foundation of China, School of Medicine, Shanghai Jiao Tong University.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer bone metastasis is a major therapeutic challenge due to poor drug selectivity and insufficient tumor targeting. Herein, we engineer a biomimetic dual bone/tumor-targeting chitosan nanogel (NG) platform (UCNG/ZOL@CM) cloaked with homologous cancer cell membranes (CM) for co-delivery of ultrasmall iron oxide nanoparticles (USIO NPs) and zoledronic acid (ZOL), enabling T1-weighted magnetic resonance (MR) imaging-guided synergistic chemo/chemodynamic therapy. The developed UCNG/ZOL@CM with an average diameter of 211.3 nm displays good colloidal stability and a pH-responsive drug release profile. Benefiting from ZOL’s bone affinity and CM-mediated homologous targeting, the platform preferentially accumulates at bone metastatic lesions. Under the acidic metastatic microenvironment, the NGs dissociate to release ZOL and USIO NPs, suppressing the mevalonate pathway while inducing Fenton/Fenton-like oxidative stress, leading to glutathione depletion, lipid peroxidation, and ferroptosis/apoptosis of cancer cells. Concurrently, acid-triggered USIO exposure enhances T1 relaxivity for improved MR imaging. In a prostate cancer bone metastasis mouse model, the UCNG/ZOL@CM enables efficient MR imaging of metastatic foci, markedly inhibits primary tumor growth and pulmonary metastasis, prolongs survival, and alleviates tumor-associated osteolysis. The developed biomimetic NG platform offers a promising theranostic strategy for precision management of prostate cancer bone metastasis.

Förderung

  • Science and Technology Commission of Shanghai Municipality
  • National Natural Science Foundation of China
  • School of Medicine, Shanghai Jiao Tong University
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Liu, J., Wang, J., Li, A., Huang, Y., Xia, L., Yang, J., Zhang, J., Shi, X., & Shen, M. (2026). Dual-Targeting Chitosan Nanogels Enable Magnetic Resonance Imaging-Guided Synergistic Chemo/Chemodynamic Therapy against Prostate Cancer Bone Metastasis. Biomacromolecules. https://doi.org/10.1021/acs.biomac.6c01943

Vancouver

Liu J, Wang J, Li A, Huang Y, Xia L, Yang J, et al. Dual-Targeting Chitosan Nanogels Enable Magnetic Resonance Imaging-Guided Synergistic Chemo/Chemodynamic Therapy against Prostate Cancer Bone Metastasis. Biomacromolecules. 2026. doi:10.1021/acs.biomac.6c01943

BibTeX
@article{Liu2026,
  author = {Liu, Jiahui and Wang, Jinxia and Li, Aiyu and Huang, Yifan and Xia, Lili and Yang, Jia and Zhang, Jianjun and Shi, Xiangyang and Shen, Mingwu},
  title = {Dual-Targeting Chitosan Nanogels Enable Magnetic Resonance Imaging-Guided Synergistic Chemo/Chemodynamic Therapy against Prostate Cancer Bone Metastasis},
  journal = {Biomacromolecules},
  year = {2026},
  doi = {10.1021/acs.biomac.6c01943}
}
Kostenlos starten →